Equities

Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

Actions
  • Price (SEK)5.61
  • Today's Change5.61 / --
  • Shares traded219.00
  • 1 Year change+28.67%
  • Beta--
Data delayed at least 20 minutes, as of Sep 09 2024 10:40 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Egetis Therapeutics AB (publ) had net income fall 68.58% from a loss of 193.80m to a larger loss of 326.70m despite revenues that grew 154.87% from 22.60m to 57.60m over the same period.
Gross margin92.12%
Net profit margin-224.92%
Operating margin-218.21%
Return on assets-33.65%
Return on equity-62.24%
Return on investment-40.07%
More ▼

Cash flow in SEKView more

In 2023, Egetis Therapeutics AB (publ) increased its cash reserves by 137.51%, or 175.60m. Cash Flow from Financing totalled 458.90m or 796.70% of revenues. In addition the company used 278.40m for operations while cash from investing was breakeven.
Cash flow per share-0.7049
Price/Cash flow per share--
Book value per share1.37
Tangible book value per share-0.0243
More ▼

Balance sheet in SEKView more

Egetis Therapeutics AB (publ) appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio1.56
Quick ratio1.55
Total debt/total equity0.2752
Total debt/total capital0.2158
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.